/NRSN
NRSN Stock - NeuroSense Therapeutics Ltd.
Healthcare|BiotechnologyNASDAQ
$0.81-1.00%
$0.01 (-1.00%) • Dec 19
46
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.2
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.57
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.89
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NRSN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.80 – $0.82
TARGET (TP)$0.93
STOP LOSS$0.75
RISK/REWARD1:2.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.56
52W High$2.60
52W Low$0.76
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-22,000 | $-97,000 | $-89,000 | $-3,000 | $-3,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-9,902,000 | $-12,049,000 | $-13,552,000 | $-5,587,000 | $-2,888,000 |
| Net Income | $-10,210,000 | $-10,107,000 | $-12,340,000 | $-4,041,000 | $-2,828,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.55 | $-0.83 | $-1.07 | $-0.23 | $-0.51 |
Company Overview
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
NRSNBeat Rate
53%
Last 15 quarters
Avg Surprise
+12.9%
EPS vs Estimate
Beats / Misses
8/6
1 met exactly
Latest EPS
$-0.04
Q4 2025
EPS Surprise History
Q4 23
+141.7%
$0.10vs$-0.24
Q1 24
+20.0%
$-0.16vs$-0.20
Q2 24
+20.0%
$-0.16vs$-0.20
Q3 24
+90.0%
$-0.02vs$-0.20
Q4 24
+31.3%
$-0.11vs$-0.16
Q2 25
+45.5%
$-0.06vs$-0.11
Q2 25
-4.8%
$-0.11vs$-0.10
Q4 25
0.0%
$-0.04vs$-0.04
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Dec 17, 2025 | — | — | — | — |
Q4 2025 | Nov 26, 2025 | $-0.04 | $-0.04 | 0.0% | = MET |
Q2 2025 | May 28, 2025 | $-0.10 | $-0.11 | -4.8% | ✗ MISS |
Q2 2025 | Apr 7, 2025 | $-0.11 | $-0.06 | +45.5% | ✓ BEAT |
Q4 2024 | Dec 18, 2024 | $-0.16 | $-0.11 | +31.3% | ✓ BEAT |
Q3 2024 | Sep 30, 2024 | $-0.20 | $-0.02 | +90.0% | ✓ BEAT |
Q2 2024 | Apr 5, 2024 | $-0.20 | $-0.16 | +20.0% | ✓ BEAT |
Q1 2024 | Mar 22, 2024 | $-0.20 | $-0.16 | +20.0% | ✓ BEAT |
Q4 2023 | Nov 28, 2023 | $-0.24 | $0.10 | +141.7% | ✓ BEAT |
Q3 2023 | Aug 16, 2023 | $-0.28 | $-0.44 | -57.1% | ✗ MISS |
Q2 2023 | Jun 1, 2023 | $-0.29 | $-0.33 | -13.8% | ✗ MISS |
Q1 2023 | Mar 22, 2023 | $-0.28 | $-0.27 | +3.6% | ✓ BEAT |
Q4 2022 | Dec 1, 2022 | $-0.28 | $-0.25 | +10.7% | ✓ BEAT |
Q3 2022 | Aug 31, 2022 | $-0.28 | $-0.31 | -10.7% | ✗ MISS |
Q2 2022 | May 31, 2022 | $-0.18 | $-0.24 | -33.3% | ✗ MISS |
Q2 2022 | Apr 14, 2022 | $-0.16 | $-0.24 | -50.0% | ✗ MISS |
Q4 2021 | Dec 10, 2021 | — | $-0.08 | — | — |
Q3 2021 | Sep 21, 2021 | — | $-0.19 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.08 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.20 | — | — |
Latest News
NeuroSense Therapeutics Locks Database For Phase 2 RoAD Study Of PrimeC In Alzheimer's; Topline Results Expected Q1 2026
➖ NeutralBenzinga•Dec 8, 2025, 07:11 PM
NeuroSense Therapeutics Resumes Regulatory Push in Canada for ALS Drug PrimeC After Productive Talks
📈 PositiveBenzinga•Dec 4, 2025, 12:32 PM
D. Boral Capital Maintains Buy on NeuroSense Therapeutics, Maintains $14 Price Target
📈 PositiveBenzinga•Nov 24, 2025, 03:46 PM
FDA Completes Review Of IND Amendment Application And Authorizes NeuroSense To Initiate Pivotal Phase 3 Clinical Trial For Evaluation Of PrimeC, For ALS Treatment
📈 PositiveBenzinga•Nov 24, 2025, 02:59 PM
Neurosense Therapeutics Announces Phase 2b PARADIGM Study Results For PrimeC Showing Statistically Significant Reductions In Multiple Micrornas Linked To Alzheimer's Disease
📈 PositiveBenzinga•Oct 6, 2025, 01:07 PM
NeuroSense Therapeutics shares are trading higher after the company reported its phase 2 RoAD trial results.
📈 PositiveBenzinga•Sep 10, 2025, 06:37 PM
NeuroSense Reports Phase 2 RoAD Trial Results, Says PrimeC Boosts Brain Connectivity In Alzheimer's, Shows Favorable Safety Profile
📈 PositiveBenzinga•Sep 10, 2025, 06:32 PM
NRSN stock has given up its prior gain. NeuroSense Therapeutics shares were trading higher after the company announced a $500,000 private placement.
➖ NeutralBenzinga•Sep 4, 2025, 02:11 PM
NeuroSense Reports Statistically Significant Survival Benefit In ALS Phase 2b PARADIGM Study; 50% Of PrimeC Patients Remain Alive
📈 PositiveBenzinga•Sep 4, 2025, 01:12 PM
NeuroSense Therapeutics shares are trading higher after the company announced a $500,000 private placement.
📈 PositiveBenzinga•Sep 4, 2025, 12:51 PM
NeuroSense Announces $500,000 Private Placement Of 333,334 Shares At $1.50/Share
📈 PositiveBenzinga•Sep 4, 2025, 12:50 PM
NeuroSense Reports Statistically Significant 18-Month Phase 2b Data Showing PrimeC Slows ALS Progression With Early Treatment Advantage
📈 PositiveBenzinga•Sep 2, 2025, 12:42 PM
NeuroSense Therapeutics Says As Of August 20, 2025, ~20% Of People With ALS From The Company's Phase 2a Study, Including Those Continuing Under Compassionate Use, Remain On Primec For More Than 5.5 Years, Having Lived With Als For Over 7 Years; Across These Multi-Year Exposures, Treatment Remains Well Tolerated, With No New Safety Signals Observed To Date
📈 PositiveBenzinga•Aug 20, 2025, 01:41 PM
Frequently Asked Questions about NRSN
What is NRSN's current stock price?
NeuroSense Therapeutics Ltd. (NRSN) is currently trading at $0.81 per share. The stock has moved -1.00% today.
What is the analyst price target for NRSN?
No analyst price targets are currently available for this stock.
What sector is NeuroSense Therapeutics Ltd. in?
NeuroSense Therapeutics Ltd. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is NRSN's market cap?
NeuroSense Therapeutics Ltd. has a market capitalization of $0.02 billion, making it a small-cap company.
Does NRSN pay dividends?
No, NeuroSense Therapeutics Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCLGN
CollPlant Biotechnologies Ltd.
$1.52
Mkt Cap: $0.0B
CVKD
Cadrenal Therapeutics, Inc. Common Stock
$7.11
Mkt Cap: $0.0B
ENLV
Enlivex Therapeutics Ltd.
$0.83
Mkt Cap: $0.0B
KLTO
Klotho Neurosciences, Inc.
$0.39
Mkt Cap: $0.0B
NERV
Minerva Neurosciences, Inc.
$4.04
Mkt Cap: $0.0B
NRXS
NeurAxis, Inc.
$3.22
Mkt Cap: $0.0B
RLYB
Rallybio Corporation
$0.79
Mkt Cap: $0.0B
SONN
Sonnet BioTherapeutics Holdings, Inc.
$1.26
Mkt Cap: $0.0B
TAOX
TAO Synergies Inc.
$5.03
Mkt Cap: $0.0B
XCUR
Exicure, Inc.
$5.92
Mkt Cap: $0.0B
Explore stocks similar to NRSN for comparison